The team at Raytheon BBN Technologies identified that a technology originally designed to detect respiratory disease in cattle could be adapted to detect COVID-19 in humans. Their lateral flow molecular assay-based LAMP test for POC COVID-19 detects the presence of the SARS-CoV-2 RNA in either saliva or nasal swab specimens, without needing to send samples to a lab.
This new solution combined the high accuracy of PCR tests with the low cost of antigen tests, without an invasive nasopharyngeal swab — representing a massive opportunity for increased testing accessibility.
Now it was time to develop a commercially viable product, with a world-class user experience.
Cortex joined a multidisciplinary team including Raytheon, Purdue University, PortaScience, and LaDuca LLC on a remote product development sprint with higher stakes than we had ever seen before.
The result is C-FAST — a passive consumable microfluidic cartridge with a simple clinical workflow that delivers accurate test results from a saliva sample in less than an hour, without the use of a lab.